GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Day One Biopharmaceuticals Inc (NAS:DAWN) » Definitions » Book Value per Share

Day One Biopharmaceuticals (Day One Biopharmaceuticals) Book Value per Share : $3.40 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Day One Biopharmaceuticals Book Value per Share?

Day One Biopharmaceuticals's book value per share for the quarter that ended in Mar. 2024 was $3.40.

During the past 12 months, Day One Biopharmaceuticals's average Book Value Per Share Growth Rate was -16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Day One Biopharmaceuticals's current price is $13.77. Its book value per share for the quarter that ended in Mar. 2024 was $3.40. Hence, today's PB Ratio of Day One Biopharmaceuticals is 4.05.

During the past 5 years, the highest P/B Ratio of Day One Biopharmaceuticals was 6.59. The lowest was 0.00. And the median was 0.00.


Day One Biopharmaceuticals Book Value per Share Historical Data

The historical data trend for Day One Biopharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Day One Biopharmaceuticals Book Value per Share Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
-0.25 -0.90 4.54 4.52 3.97

Day One Biopharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.08 4.90 4.48 3.97 3.40

Competitive Comparison of Day One Biopharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Day One Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Day One Biopharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's PB Ratio falls into.



Day One Biopharmaceuticals Book Value per Share Calculation

Day One Biopharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(346.54-0.00)/87.23
=3.97

Day One Biopharmaceuticals's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(296.81-0.00)/87.38
=3.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Day One Biopharmaceuticals  (NAS:DAWN) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Day One Biopharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Day One Biopharmaceuticals (Day One Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2000 Sierra Point Parkway, Suite 501, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Executives
York Charles N Ii officer: COO, CFO and Secretary 901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746
Samuel C. Blackman officer: Chief Medical Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Jeremy Bender director, officer: Chief Executive Officer 395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Ai Day 1 Llc 10 percent owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Julie Papanek Grant director 2765 SAND HILL ROAD, MENLO PARK CA 94025
Canaan Xi L.p. 10 percent owner 2765 SAND HILL RD, MENLO PARK CA 94025
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Michael Gladstone director 395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Takeda Ventures, Inc. 10 percent owner 9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
J. Scott Garland director 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John A. Josey director C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235

Day One Biopharmaceuticals (Day One Biopharmaceuticals) Headlines

From GuruFocus

This Insider Just Sold Shares of Day One Biopharmaceuticals Inc

By GuruFocus Research GuruFocus Editor 05-18-2023

Day One Announces Pricing of Public Offering of Common Stock

By GlobeNewswire GlobeNewswire 06-07-2023